We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Key Factors Signal Infection Risk in Alcoholic Hepatitis

By LabMedica International staff writers
Posted on 17 Aug 2021
Print article
Image: Histopathology shows extensive liver cell damage resulting from alcoholic hepatitis (Photo courtesy of The Johns Hopkins University)
Image: Histopathology shows extensive liver cell damage resulting from alcoholic hepatitis (Photo courtesy of The Johns Hopkins University)
Alcohol-associated hepatitis (AAH) is a severe form of liver injury with mortality as high as 30%-40% at 90 days. As a result of altered immune function in AAH, bacterial infections are common and are associated with poor outcomes.

Severe cases of AAH are characterized by new onset jaundice. Infections are common in severe AAH, with approximately 25% of patients presenting with community-acquired infection and a similar percentage found to develop nosocomial infections. The high rates of sepsis observed in AAH may be explained by the impact of alcohol excess on the immune system.

Gastroenterologists and their colleagues at the Mayo Clinic Rochester (Rochester, MN, USA) performed a retrospective study of consecutive patients admitted with a diagnosis of AAH at two independent tertiary centers from 1998 to 2018 (test cohort, n = 286) who developed infections following hospitalization. The cohort was 66% men, and the median age was 48 (range: 21-83) years. Corticosteroids were used in 32% of all patients with AAH.

Patients were diagnosed with AAH based on the clinical criteria and laboratory data including aspartate aminotransferase (AST) >50, aspartate aminotransferase/alanine aminotransferase (ALT) ratio >1.5, AST/ALT <400 IU/L, and serum bilirubin (total) >3.0 mg/dL. When the diagnosis of AAH remained unclear, a liver biopsy was obtained for confirmation. Types of infection were categorized as a urinary tract infection (UTI), bloodstream infection (BSI), pneumonia (PNA), spontaneous bacterial peritonitis (SBP), and Clostridium difficile (C. diff).

The scientists reported that the overall incidence of infection in the cohort was 36% (n = 102). They then excluded those who presented to the hospital with community-acquired infection, which was 12% (n = 34) of patients. The most common sources of infection at presentation were UTI (12), BSI (10), lower respiratory (6), SBP (3), and C. diff (3), and the most commonly identified organisms included Escherichia coli (8) and Staphylococcus aureus (6). Of those who developed an infection while hospitalized (31/286), the most common infection sources included lower respiratory tract infections (10), BSI (7), SBP (6), UTI (6), and C. diff (2).

Daniel Penrice, MD, a co-author of the study, said, “Our hope is that future studies can evaluate whether targeted prophylactic antibiotics for patients at high-risk for infection can improve survival. Our prediction model can likely be strengthened by the inclusion of novel biomarkers such as circulating serum bacterial DNA, endotoxin, or bacterial 16S ribosomal DNA.”

The authors concluded that in this multicenter cohort study of patients hospitalized with AAH, MELD score, ascites, WBC count, and use of corticosteroids were identified as significant predictors of the development of bacterial infection. They created a novel predictive equation that may be used to aid in the identification of patients with AAH at high risk of infection. The study was published on July 28, 2021 in the journal Hepatology Communications.

Related Links:
Mayo Clinic Rochester

Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Silver Member
H-FABP Assay
Heart-Type Fatty Acid-Binding Protein Assay
New
Creatine Kinase-MB Assay
CK-MB Test

Print article

Channels

Clinical Chemistry

view channel
Image: A one-step confirmatory laboratory test could definitively diagnose active syphilis infection within 10 minutes (Photo courtesy of Adobe Stock)

First Comprehensive Syphilis Test to Definitively Diagnose Active Infection In 10 Minutes

In the United States, syphilis cases have surged by nearly 80% from 2018 to 2023, with 209,253 cases recorded in the most recent year of data. Syphilis, which can be transmitted sexually or from mother... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.